Synapse - Matthew Matasar

Results (37)

Characterization of CD20 expression loss as a mechanism of resistance to mosunetuzumab in patients with relapsed/refractory B-cell non-Hodgkin lymphomas

Meeting Abstract

Schuster, S. J.; Huw, L. Y.; Bolen, C. R.; Assouline, S. E.; Bartlett, N. L.; Budde, L. E.; Matasar, M. J.; Koeppen, H.; Piccione, E. C.; Wilson, D.; more...
Journal of Clinical Oncology (2022)

Fulltext@MSK | Save

Initial safety run-in results of the phase III POLARGO trial: Polatuzumab vedotin plus rituximab, gemcitabine, and oxaliplatin in patients (pts) with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL)

Meeting Abstract

Matasar, M. J.; Haioun, C.; Sancho, J. M.; Viardot, A.; Izquierdo, A. R.; Martin, E. M. D.; Garcia-Sancho, A. M.; Sandoval-Sus, J. D.; Tilly, H.; Vandenberghe, E.; more...
Journal of Clinical Oncology (2022)

Fulltext@MSK | Save

Single-agent mosunetuzumab shows durable complete responses in patients with relapsed or refractory b-cell lymphomas: Phase 1 dose-escalation study

Journal Article

Budde, L. E.; Assouline, S.; Sehn, L. H.; Schuster, S. J.; Yoon, S. S.; Yoon, D. H.; Matasar, M. J.; Bosch, F.; Kim, W. S.; Nastoupil, L. J.; more...
Journal of Clinical Oncology (2022)

Fulltext@MSK | Save

Copanlisib + rituximab versus rituximab + placebo in patients with relapsed follicular (FL) or marginal zone lymphoma (MZL): Subset analysis from the phase III CHRONOS-3 trial

Meeting Abstract

Matasar, M. J.; Capra, M.; Özcan, M.; Lv, F.; Li, W.; Yanez, E.; Sapunarova, K.; Lin, T.; Jin, J.; Jurczak, W.; more...
Journal of Clinical Oncology (2021)

Fulltext@MSK | Save

ESCALADE: A phase 3 study of acalabrutinib in combination with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for patients ≤65y with untreated non-germinal center B-cell-like (non-GCB) diffuse large B-cell lymphoma (DLBCL)

Meeting Abstract

Sehn, L. H.; Kahl, B. S.; Matasar, M. J.; Lenz, G.; Izutsu, K.; Zhao, W.; Tao, L.; Calvo, R.; Zinzani, P. L.
Journal of Clinical Oncology (2021)

Fulltext@MSK | Save

Update of a phase II, multicenter study of high-dose chemotherapy with autologous stem cell transplant followed by maintenance romidepsin for T-cell lymphoma

Meeting Abstract

Khan, N.; Khimani, F.; Shustov, A. R.; Shadman, M.; Ruan, J.; Moskowitz, A. J.; Straus, D. J.; Kumar, A.; Sauter, C. S.; Zelenetz, A. D.; more...
Journal of Clinical Oncology (2021)

Fulltext@MSK | Save

Provision of subspecialized expert oncology (SEO) opinions using Navya Cancer Data Model (NCDM), a technology-based platform: Prospective study to facilitate access to care

Meeting Abstract

Traina, T. A.; Kantoff, P. W.; Matasar, M. J.; Dunn, L.; Friedman, C. F.; Voss, M. H.; Seidman, A. D.; Cahlon, O.; Zauderer, M. G.; Manship, C.; more...
Journal of Clinical Oncology (2021)

Fulltext@MSK | Save

Phase II trial of pembrolizumab plus gemcitabine, vinorelbine, and liposomal doxorubicin as second-line therapy for relapsed or refractory classical Hodgkin lymphoma